順威股份(002676.SZ):控股股東名稱變更為“廣州開投智造產業投資集團有限公司”
格隆匯2月16日丨順威股份(002676.SZ)公佈,公司於2022年2月16日收到公司控股股東廣州開發區智造產業投資有限公司的《吿知函》,經廣州市黃埔區市場監督管理局核准,公司控股股東企業名稱已變更為“廣州開投智造產業投資集團有限公司”,同時控股股東法定代表人由張放變更為陳棟恆,控股股東董事兼總經理由蘇雲華變更為陳棟恆。上述變更均已完成工商變更登記手續,並取得廣州市黃埔區市場監督管理局換髮的營業執照。除上述名稱、法定代表人及董事兼總經理變更外,其餘工商登記註冊信息未發生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.